Saturday 17 October 2026
Export INFU’s income statement to Excel — free account
InfuSystems Holdings, Inc.
INFU Healthcare Medical Devices
InfuSystems Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $143.4 million, up 6.36% from fiscal 2024. In the quarter to June 2026, revenue grew 2.59%, EPS grew 33.3%, free cash flow fell 66.5% and total debt fell 22.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
13.33
0.59
−4.24%
Follow INFU
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
39.85 | 28.03 | 24.29 | 22.98 |
P/S ratio |
1.50 | 1.29 | 1.31 | 1.35 | |
P/FCF ratio |
36.69 | 30.70 | 28.15 | 90.30 | |
P/Operating CF |
24.90 | 26.00 | 192.32 | 28.58 | |
P/B ratio |
3.81 | 3.23 | 3.18 | 3.27 | |
Price to Tangible BV |
4.73 | 3.96 | 3.86 | 3.96 | |
EV/Sales |
1.64 | 1.41 | 1.43 | 1.49 | |
EV/EBITDA |
9.54 | 7.98 | 7.80 | 8.02 | |
EV/Operating CF |
9.19 | 8.27 | 8.66 | 9.13 | |
EV/FCF |
40.18 | 33.45 | 30.82 | 99.44 | |
Quick Ratio |
1.35 | 1.29 | 1.52 | 1.84 | |
Current Ratio |
1.90 | 1.80 | 2.14 | 2.50 | |
Net Debt/EBITDA |
2.81 | 2.32 | 3.61 | 2.59 | |
Debt/Assets |
21.17% | 19.52% | 19.91% | 20.90% | |
Debt/Equity |
0.38 | 0.34 | 0.33 | 0.35 | |
Asset Turnover |
1.38 | 1.41 | 1.40 | 1.44 | |
Operating CF/Net income |
3.76 | 3.50 | 0.95 | 2.10 | |
Capex/Depreciation |
(0.08) | (0.65) | (0.38) | (1.34) | |
Interest Coverage |
11.55 | 14.28 | 6.24 | 16.28 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
46.62% | 46.15% | 53.71% | 46.74% | |
Intangible Assets out of Total Assets |
0.11 | 0.11 | 0.11 | 0.10 | |
Share Based Compensation of Revenue |
3.62% | 3.51% | 3.66% | 3.36% | |
Graham Net Nets |
(0.04) | (0.04) | (0.02) | 0.00 | |
Graham Number |
3.99 | 4.47 | 4.99 | 5.28 | |
Earnings Yield |
2.51% | 3.57% | 4.12% | 4.35% | |
Free Cash Flow Yield |
2.73% | 3.26% | 3.55% | 1.11% | |
Revenue per Share |
1.79 | 1.75 | 1.67 | 1.84 | |
Operating CF per Share |
0.42 | 0.35 | 0.05 | 0.34 | |
Capex per Share |
(0.01) | (0.11) | (0.06) | (0.23) | |
Free Cash Flow per Share |
0.40 | 0.24 | (0.01) | 0.11 | |
Cash per Share |
0.05 | 0.15 | 0.10 | 0.05 | |
Shareholders Equity per Share |
2.72 | 2.78 | 2.91 | 2.95 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.72 | 2.78 | 2.91 | 2.95 | |
Free Cash Flow |
8.24 | 4.93 | (0.29) | 2.25 | |
Working Capital |
16.85 | 16.15 | 19.52 | 22.97 | |
Capital Expenditures |
(0.25) | (2.19) | (1.26) | (4.52) | |
Net Current Asset Value |
(7.84) | (6.90) | (3.25) | (0.28) | |
EV/EBIT |
21.40 | 16.94 | 15.84 | 16.08 | |
Capex to Sales |
0.01 | 0.06 | 0.04 | 0.12 | |
Price to Operating Income |
19.54 | 15.55 | 14.47 | 14.60 | |
| Other line items | |||||
Average Receivables |
23.54 | 22.03 | 23.94 | 25.84 | |
Average Payables |
9.47 | 10.33 | 9.00 | 9.15 | |
Average Inventory |
6.15 | 5.96 | 5.96 | 5.59 | |
Average Assets |
102.09 | 102.09 | 101.47 | 99.27 | |
Average Common Equity |
55.49 | 57.43 | 56.95 | 56.84 |
Columns are period end dates